Given that CRC is a heterogeneous disease with genetic profiles and clinical outcomes associate with the anatomic location of the primary tumor, these results could not exclude the possibility of MAGI3/LPA2 interaction in some distinct types of CRC. This evidence concerns the gene LPAR2 and colorectal carcinoma.